Gastrointestinal Infections

Top Story

ENYO Pharma obtains license for receptor to potentially treat HBV

February 5, 2016

ENYO Pharma announced it has entered a patent licensing agreement with Inserm Transfert and other necessary parties and obtained a license to a key patent for it to use agonists of the farnesoid X receptor for the treatment of hepatitis B virus infection.

The farnesoid X receptor (FXR), a nuclear and bile acid receptor, regulates replication of HBV and controls what happens to bile acids in the liver and intestine and can also influence insulin sensitivity. The use of FXR agonists for the treatment of HBV was first discovered and patented by Inserm research scientists and their industry partners Poxel and Edelris.

USDA finalizes new food safety standards for poultry

February 4, 2016
The Agriculture Department’s Food Safety and Inspection Service, or FSIS, announced that new federal standards have been finalized that will reduce Salmonella
In the Journals

S. boulardii probiotic does not reduce antibiotic, C. difficile diarrhea

February 4, 2016
Administration of a Saccharomyces boulardii probiotic treatment to hospital patients receiving antibiotics appeared to have no impact on the incidence of antibiotic-…

CDC closes investigation on two E. coli outbreaks linked to Chipotle

February 1, 2016
The CDC recently announced that two Escherichia coli outbreaks linked to food served at Chipotle Mexican Grill restaurants appear to be over. Since the last update in…

ENYO Pharma obtains license for receptor to potentially treat HBV

February 5, 2016
ENYO Pharma announced it has entered a patent licensing agreement with Inserm Transfert and other necessary parties and obtained a license to a key…

USDA finalizes new food safety standards for poultry

February 4, 2016
The Agriculture Department’s Food Safety and Inspection Service, or FSIS, announced that new federal standards have been finalized that will…
In the Journals

S. boulardii probiotic does not reduce antibiotic, C. difficile diarrhea

February 4, 2016
Administration of a Saccharomyces boulardii probiotic treatment to hospital patients receiving antibiotics appeared to have no impact on the…

CDC closes investigation on two E. coli outbreaks linked to Chipotle

February 1, 2016
The CDC recently announced that two Escherichia coli outbreaks linked to food served at Chipotle Mexican Grill restaurants appear to be over. Since…
In the Journals

HBV cases increase among IDUs in Appalachian states

February 1, 2016
The incidence of hepatitis B virus infection appears to have increased in three Appalachian states from 2006 to 2013, especially among injection drug…
In the Journals

Booster vaccine against HBV not needed, researchers find

February 1, 2016
A majority of Alaska natives showed signs of protection against hepatitis B virus infection 30 years after receiving a primary vaccination series…
FDA News

FDA: Cheese manufacturer pleads guilty to breaking food safety laws

January 30, 2016
The FDA reported that a cheese manufacturer in Kenton, Delaware, has pleaded guilty to violating federal food and drugs laws during a Listeria
FDA News

FDA accepts Merck’s biologics license application for bezlotoxumab

January 27, 2016
The FDA has accepted Merck’s biologics license application for bezlotoxumab, an antitoxin developed for the prevention of recurring…
In the Journals

Novel clonotyping test predicts E. coli susceptibility

January 26, 2016
A novel method of clonotyping extraintestinal pathogenic Escherichia coli could enable clinicians and epidemiologists to predict antimicrobial…
In the Journals

Judicious C. difficile sampling reduces cost burden of overtesting

January 26, 2016
Automatic rejection of nondiarrheal samples submitted for Clostridium difficile infection testing significantly reduced patient and hospital costs…
More Headlines »
morganatic-roan